Zobrazeno 1 - 10
of 29
pro vyhledávání: '"T. A. Chalyabi"'
Autor:
S. V. Nedogoda, T. N. Sanina, T. A. Chalyabi, I. N. Barykina, V. V. Tsoma, E. V. Chumachek, A. S. Salasyuk, V. Y. Khripaeva, V. O. Smirnova
Publikováno v:
Медицинский совет, Vol 0, Iss 11, Pp 66-69 (2014)
According to recent guidelines of AASLD, AGA and ACG, NAFLD is a liver disease accompanied by the accumulation of fatty acid content greater than 5% of hepatocytes weight, absence of substantial alcohol consumption (20 g per day for men, 10 g per day
Externí odkaz:
https://doaj.org/article/6d431c39814045c294cc3149d342a7e0
Autor:
S. V. Nedogoda, T. A. Chalyabi, A. S. Salasyuk, I. N. Barykina, D. A. Pocheptsov, A. A. Ledyaeva, V. V. Tsoma, E. V. Chumachek
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 56-64 (2013)
Algorithm for selection of antihypertensive treatment in patients with metabolic syndrome and hypertension ACE inhibitors and angiotensin II receptor blockers are major antihypertensive classes of drugs used in the treatment of hypertension in patien
Externí odkaz:
https://doaj.org/article/1976f806669e4e43a918d6de8e90977a
Autor:
S. V. Nedogoda, I. N. Barykina, U. A. Brel, T. A. Chalyabi, G. V. Mazina, E. V. Podolskaya, A. A. Ledyaeva
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 8, Iss 4, Pp 23-27 (2009)
Aim. To investigate the potential of sibutramine (Meridia®) therapy in patients with obesity and arterial hypertension (AH); to assess sibutramine effects on blood pressure (BP), organ protection and quality of life (QoL) in individuals with obesity
Externí odkaz:
https://doaj.org/article/f2d71704503e42129b0400e63ad630a0
Autor:
S. V. Nedogoda, I. N. Barykina, T. A. Chalyabi, L. V. Butrina, U. A. Brel, G. V. Mazina, E. A. Podolskaya
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 8, Iss 1, Pp 88-98 (2009)
The review is devoted to the features of antihypertensive therapy (AHT) in arterial hypertension combined with obesity. Pathogenesis of blood pressure increase in obesity is emphasised. The authors analyse the safety of various antihypertensive medic
Externí odkaz:
https://doaj.org/article/e91d40c56ee349228476b69fb19bace1
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 7, Iss 6, Pp 21-27 (2008)
Aim. To assess the effectiveness of fixed-dose combination of enalapril maleate (20 mg) and hydrochlorothiazide (12,5 mg) - Enap NL 20, comparing to arbitrary combinations of two antihypertensive medications (АНМ), in patients with Stage I-III art
Externí odkaz:
https://doaj.org/article/aa0bb398964e463386d4da1e14c82dce
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 7, Iss 5, Pp 105-115 (2008)
The review is devoted to the problem of arterial hypertension (AH) combined with obesity. Pharmaceutical and non-pharmaceutical methods for weight reduction, as well as their effects on blood pressure (BP), are emphasised. Sibutramine safety in AH an
Externí odkaz:
https://doaj.org/article/6485bee6d72045149af66b4ad0d8164f
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 6, Iss 6, Pp 10-14 (2007)
Aim. To compare clinical effectiveness and tolerability of original (Cozaar®) and generic (Lozap®) losartan in high and very high-risk patients with Stage I-II arterial hypertension (AH). Material and methods. This blind, randomized (envelope metho
Externí odkaz:
https://doaj.org/article/d9df7160c50047788b246194dda17892
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 6, Iss 3, Pp 11-18 (2007)
Aim. To assess and compare 6-month monotherapy effectiveness for losartan and lisinopril, according to their effects on blood pressure (BP), vascular elasticity, and cognitive function in patients with Stage I-II arterial hypertension (AH). Material
Externí odkaz:
https://doaj.org/article/ae4fd389eb1f4c62bd3f592669c629e0
Acarbose effects on vascular stiffness in patients with arterial hypertension and metabolic syndrome
Autor:
S. V. Nedogoda, V. A. Tsoma, I. N. Barykina, G. V. Mazina, U. A. Brel, T. A. Chalyabi, V. B. Mychka, I. E. Chazova
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 5, Iss 2, Pp 40-45 (2006)
Aim. To assess perspectives of pulse wave velocity (PWV) correction during acarbose treatment in patients with impaired glucose tolerance (IGT) and arterial hypertension (AH). Material and methods. An open clinical trial included 45 patients (18 male
Externí odkaz:
https://doaj.org/article/bfc0060c56bc487bbf921902e28546a2
Autor:
S. V. Nedogoda, I. V. Marchenko, T. A. Chalyabi, U. A. Brel, V. A. Tsoma, E. A. Prokhorova, E. S. Kesareva
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 4, Iss 3, ч.I, Pp 40-45 (2005)
Aim. To assess perspectives of decreasing individual cardiovascular event (CVE) risk and surrogate end-point incidence (blood pressure, BP; left ventricular hypertrophy, LVH; pulse wave velocity, PWV), in high- and very high-risk patients with Stage
Externí odkaz:
https://doaj.org/article/9a1b2d901cc74d41967eba263d95383d